The Diagnosis Confirmation Model (DCM) includes a dual-pricing mechanism designed to support value-based pricing of novel antibiotics while improving the alignment of financial incentives with their optimal use in patients at high risk of drug-resistant infections. DCM is a market-based model and complementary to delinked models. Policymakers interested in stimulating antibiotic innovation could consider tailoring the DCM to their reimbursement systems and incorporating it into the suite of incentives to improve the economics of antibiotics.
CITATION STYLE
Lum, K., Bhatti, T., Holland, S., Guthrie, M., & Sassman, S. (2018). Diagnosis Confirmation Model: A Value-Based Pricing Model for Inpatient Novel Antibiotics. The Journal of Law, Medicine & Ethics : A Journal of the American Society of Law, Medicine & Ethics, 46(1), 66–74. https://doi.org/10.1177/1073110518782917
Mendeley helps you to discover research relevant for your work.